Genedx Holdings Corp WGS

$73.09 +2.13 (3.00%)

Valuation

Market cap
2,116,240,000
Revenue TTM
$427,540,000
Net income TTM
$-21,020,000
PE ratio
200.83
Forward PE
—
Profit margin
-4.92%
Debt to equity
0.40

Trading

Volume
606,600
Avg volume
741,546
Day's range
$70.48 – $74.86
Shares out
29,823,000
Stochastic %K
11%
Beta
1.95
Analysts
Strong Sell
Price target
$91.44

Price

Company profile

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx H...

Show more

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Industry
Diagnostics & Research
Sector
Healthcare
Phone
888 729 1206
Website
https://www.genedx.com
Address
North Tower, 6th Floor 333 Ludlow Street, Stamford, United States

Latest news

Stocktwits

BB_88_ Oct 2, 5:47 PM
$WGS moving - let’s go
0 replies
BB_88_ Oct 2, 5:33 PM
$WGS think they cover today
0 replies
BB_88_ Oct 2, 5:29 PM
$WGS in
0 replies
tradebyfire Oct 1, 8:35 PM
$WGS 60’s on deck for next support?
1 replies
BB_88_ Oct 1, 7:49 PM
$WGS spike before close 🤷‍♂️
0 replies
BB_88_ Oct 1, 6:56 PM
$WGS expect a close over 73
0 replies
BB_88_ Oct 1, 6:42 PM
$WGS in here
0 replies
Humtake Sep 30, 7:13 PM
$WGS Biotech doing great today and this ticker is still going down. Not sure what to think of this. The only negative is the absurd lawsuits due to whiners who lost money and it hurt their egos because institutional investors can't accept they aren't in control of everything. Can't wait until genomic medicine becomes the norm to see if those investors can still find a way to make mm believable enough to not be sued themselves.
0 replies